Biologics to restore healthy immune regulation

Q32 Bio is focused on developing targeted biotherapeutics aimed at rebalancing the immune system to treat severe inflammatory and autoimmune diseases. Their lead product candidate, Bempikibart (ADX-914), is a fully human monoclonal antibody that acts as an antagonist to the interleukin-7 receptor alpha (IL-7Rα). By blocking IL-7 and thymic stromal lymphopoietin (TSLP) signaling, Bempikibart aims to re-regulate adaptive immune function. Currently, it is undergoing evaluation in Phase 2 clinical trials for atopic dermatitis and alopecia areata, with promising data from earlier trials indicating its tolerability and pharmacokinetic profile.

In addition to Bempikibart, Q32 Bio is advancing ADX-097, a humanized anti-C3d monoclonal antibody fusion protein designed to restore complement regulation within the innate immune system. This candidate is part of a novel tissue-targeted complement inhibitor platform, which has shown potential therapeutic activity in various diseases where C3 complement fragments are involved. ADX-097 is currently being evaluated in a Phase 2 clinical trial for renal diseases and is also planned for trials in ANCA-associated vasculitis. The development of these therapies reflects Q32 Bio's commitment to addressing significant unmet medical needs in immune-mediated conditions.

United States

Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.

Q32 Bio

Company Details